Long-held hypothesis that iron promotes atherosclerosis challenged by study
A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis, the hardening and narrowing of the arteries that leads to cardiovascular disease, the No. 1 killer in the U.S.The discovery, based on a comprehensive study in a mouse model of atherosclerosis, contradicts a long-held hypothesis about the role of iron in the disease and carries important implications for patients with chronic kidney disease or anemia related to inflammatory disorders, many of whom receive high-dose iron supplementation therapy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 23, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

US experts say high blood pressure is overtreated
Conclusion These US derived guidelines do not change how doctors in the UK will help care for people with high blood pressure. But they will provide focus for further expert debate on the issue of treating hypertension in this country. As the guideline authors note in their conclusion, the guidance does not change the definition of high blood pressure (140/90mmHg or higher), and that the recommendations are not a substitute for clinical judgement (for example, doctors making treatment decisions based on the overall health of their patient and the patient’s preferences). The guideline authors say decisions about care...
Source: NHS News Feed - December 20, 2013 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Cancer death risk increases with chronic kidney disease
Cancer sufferers are more likely to die from their condition if their kidneys are not functioning properly, a new study published online in the American Journal of Kidney Diseases claims.Dr. Germaine Wong from the University of Sydney led the research, which shows that even mild to moderate reduction in kidney function increased the rate of cancer mortality.According to the National Kidney Foundation, 26 million Americans have kidney disease, but as it does not have symptoms until it is advanced, it often goes undiagnosed. Dr. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

FDA grants approval of a Phase 3 pivotal study for ST10 for the treatment of iron deficiency anaemia in chronic kidney disease
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with chronic kidney disease (CKD). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Body mass index 'in and of itself' increases risk of developing chronic kidney disease
A new UCSF-led study of nearly 3,000 individuals links obesity to the development of kidney disease. The work also shows that, when properly measured, declines in kidney function are detectable long before the emergence of other obesity-related diseases such as diabetes and high blood pressure.Healthy kidneys are vital to the proper functioning of the heart and brain, as well as the skeletal and immune systems, and the research adds additional urgency to the call for doctors to intervene early in life with obese patients, the researchers said. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2013 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

UCLA study challenges long-held hypothesis that iron promotes atherosclerosis
A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis, the hardening and narrowing of the arteries that leads to cardiovascular disease, the No. 1 killer in the U.S.   The discovery, based on a comprehensive study in a mouse model of atherosclerosis, contradicts a long-held hypothesis about the role of iron in the disease and carries important implications for patients with chronic kidney disease or anemia related to inflammatory disorders, many of whom receive high-dose iron supplementation therapy. The findings currently appear online ...
Source: UCLA Newsroom: Health Sciences - December 17, 2013 Category: Universities & Medical Training Source Type: news

Antihypertensives appear associated with lower risk for dialysis in patients with advanced chronic kidney disease
Patients with stable hypertension and the most advanced stage of chronic kidney disease (CKD) before dialysis appeared to have a lower risk for long-term dialysis or death if they were treated with the antihypertensive drugs known as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), according to a study published by JAMA Internal Medicine, a JAMA Network publication. An ACEI or ARB is known to delay the progression of CKD in patients with and without diabetes, particularly in those patients with mild to moderate renal insufficiency. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Physical activity may slow kidney function decline in patients with kidney disease
Increased physical activity may slow kidney function decline in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that exercise could have a powerful effect on maintaining patients' health.Approximately 60 million people globally have chronic kidney disease (CKD). In the past 20 years, few new interventions have been shown to be useful in slowing the progression of the disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

ACE-Inhibitors and ARBs Associated with Reduced Need for Dialysis in Advanced CKD (FREE)
By Kelly Young Use of either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) — but not the two together — may reduce the need for dialysis in patients with advanced chronic kidney disease, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 17, 2013 Category: Primary Care Source Type: news

UCLA study challenges long-held hypothesis that iron promotes atherosclerosis
(University of California - Los Angeles Health Sciences) A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis. The discovery, based on a comprehensive study in a mouse model of atherosclerosis, contradicts a long-held hypothesis about the role of iron in the disease and carries important implications for patients with chronic kidney disease or anemia related to inflammatory disorders, many of whom receive high-dose iron supplementation therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2013 Category: Global & Universal Source Type: news

ACE or ARB Each Effective in Advanced Kidney Disease (CME/CE)
(MedPage Today) -- The use of ACE inhibitors or angiotensin receptor blockers (ARBs) in patients with advanced chronic kidney disease and hypertension may have prevented the initiation of long-term dialysis and delayed death, a Taiwanese study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 16, 2013 Category: Cardiology Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include the risk of overdiagnosis of lung cancers with low-dose CT, genotype impact on Coumadin dosing, diabetes and hypoglycemia risk, and cholesterol management in folks with chronic kidney disease. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 13, 2013 Category: Cardiology Source Type: news

The Future of NephrologyThe Future of Nephrology
'We need to be truly expert' in managing chronic kidney disease, says Dr. Jeffrey Berns, in order to preserve the specialty of nephrology. Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Nephrology Commentary Source Type: news

RAA Inhibitors Tied to Longer Survival With Chronic Kidney DiseaseRAA Inhibitors Tied to Longer Survival With Chronic Kidney Disease
Patients with chronic kidney disease (CKD) who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) survive longer than those not on the drugs, according to a study of more than 40,000 U.S. veterans. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2013 Category: Consumer Health News Tags: Medscape Today News Source Type: news

ACP issues policy paper on prescription drug abuse; Guidelines recommend wider statin use among adults with chronic kidney disease
1. American College of Physicians issues policy calling for tighter management of prescription drugsIn a new policy paper published in Annals of Internal Medicine, the American College of Physicians (ACP) recommends clinical and administrative changes that will make it harder for prescription drugs, such as those prescribed for pain, sleep disorders, and weight loss, to be abused or diverted for sale on the street. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2013 Category: Consumer Health News Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Lipid Management with Statins/Ezetimibe Proposed for Chronic Kidney Disease (FREE)
By Joe Elia The Kidney Disease: Improving Global Outcomes (KDIGO) group is recommending that patients with chronic kidney disease receive lipid management with either statins alone or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 10, 2013 Category: Primary Care Source Type: news

CKD: KDIGO Guidelines Recommend Wider Use of Statins CKD: KDIGO Guidelines Recommend Wider Use of Statins
The Kidney Disease: Improving Global Outcomes group has developed a clinical practice guideline on lipid management, particularly statin use, for patients with chronic kidney disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news

LDL No Longer Target of Kidney Disease Lipid Management (CME/CE)
(MedPage Today) -- Specific LDL cholesterol treatment targets were removed from guidelines on managing lipids in patients with chronic kidney disease (CKD) released by Kidney Disease: Improving Global Outcomes (KDIGO) last month. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 9, 2013 Category: Cardiology Source Type: news

Guidelines recommend wider statin use among adults with chronic kidney disease
Guidelines from the Kidney Disease: Developing Global Guidelines (KDIGO) organization call for wider statin use among patients with chronic kidney disease (CKD). KDIGO updated its clinical practice guidelines for lipid management in patients with CKD earlier in 2013. A synopsis of these guidelines being published in Annals of Internal Medicine focuses on eight specific recommendations relating to pharmacological cholesterol-lowering among adult patients with CKD. Patients recommended for statin use include adults aged 50 or older with eGFR
Source: Health News from Medical News Today - December 9, 2013 Category: Consumer Health News Tags: Statins Source Type: news

FDA Clears New Phosphate Binder VelphoroFDA Clears New Phosphate Binder Velphoro
Sucroferric oxyhydroxide (Velphoro) is an iron-based, calcium-free, chewable phosphate binder for treatment of hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2013 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

African Americans with chronic kidney disease at increased risk for end-stage renal disease
In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University (GW) researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 2, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Vifor Pharma's hyperphosphatemia drug Velphoro gets FDA approval
The US Food and Drug Administration (FDA) has approved Vifor Pharma's hyperphosphatemia drug Velphoro for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 2, 2013 Category: Pharmaceuticals Source Type: news

Mesoamerican Nephropathy: Pathological CharacteristicsMesoamerican Nephropathy: Pathological Characteristics
Are some rural inhabitants in parts of Central America susceptible to an endemic form of chronic kidney disease? This new study looks at the possible reasons. American Journal of Kidney Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2013 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Velphoro (PA21) receives US FDA approval for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis
Velphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Velphoro® will be launched in the US by Fresenius Medical Care North America in 2014.Velphoro® (previously known as PA21) is an iron-based, calcium-free, chewable phosphate binder. US approval was based on a pivotal Phase III study, which met its primary and secondary endpoints. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 29, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news

OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) -...
MarketResearch.com announces the addition of a new market research report to their product offering: OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts...(PRWeb November 27, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11363139.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 28, 2013 Category: Pharmaceuticals Source Type: news

High salt levels in soluble drugs may raise heart risk
Conclusion This large case control study suggested that people who had experienced disease of the heart and blood vessels were more likely to have taken sodium-containing medicines than people without cardiovascular disease. Put in other words this can be interpreted that people who took sodium-containing medicines were at a higher risk of experiencing cardiovascular disease than people who took the same medications in formulations free of sodium. The increased risk appeared to be driven mostly by an increased risk of hypertension and to a lesser extent, non-fatal stroke. The study has some strengths including its large s...
Source: NHS News Feed - November 27, 2013 Category: Consumer Health News Tags: Heart/lungs Medication Medical practice Source Type: news

ACE Inhibitors Cut Mortality in Renal Patients
(MedPage Today) -- Chronic kidney disease patients who did not depend on dialysis were significantly less likely to die during the study period if they received angiotensin converting enzyme inhibitors or angiotensin receptor blockers, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2013 Category: Cardiology Source Type: news

OPKO closes patient recruitment in first Phase III study of Rayaldy
OPKO Health has closed patient enrolment in the first Phase III trial of Rayaldy for the treatment of patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. (Source: Drug Development Technology)
Source: Drug Development Technology - November 19, 2013 Category: Pharmaceuticals Source Type: news

APOL1 Variants Increase Renal Risk in Black PatientsAPOL1 Variants Increase Renal Risk in Black Patients
Gene variants heighten the risk for chronic kidney disease, regardless of blood pressure control and diabetes status. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news

New Hope For Dialysis Patients As ‘Immune-Fingerprints' Discovered
University scientists who are committed to developing improved treatments for patients with chronic kidney disease have discovered a novel way of significantly accelerating the detection of bacterial infection using the patient’s own immune system. (Source: Medical Design Online News)
Source: Medical Design Online News - November 15, 2013 Category: Medical Equipment Source Type: news

New research defines the cardiovascular risk factors associated with chronic kidney disease
New research presented at the Euro-Chapter of the International Union of Angiology has identified the potential for screening early risk factors of chronic kidney disease1 (CKD). There are an estimated 45,000 premature deaths annually associated with the disease2. The research, a collaboration between Imperial College London and Life Line Screening, collected data from nearly 3,000 Irish and British individuals who had self-selected for cardiovascular check-ups. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 14, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Novel Therapy Shows Safety, Efficacy in HyperkalemiaNovel Therapy Shows Safety, Efficacy in Hyperkalemia
Phase 2 and preliminary phase 3 results show significant reductions in potassium and a good safety profile in patients with chronic kidney disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news

Ferinject® reduces or delays requirement for alternative anaemia management compared with oral iron therapy
Results from the FIND-CKD study were presented at the American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia, USA. The FIND-CKD results demonstrate that Ferinject® (ferric carboxymaltose) targeting a serum ferritin of 400-600 ug/L in patients with non-dialysis-dependent chronic kidney disease (ND-CKD) and iron deficiency anaemia significantly reduces or delays the need for alternative anaemia management (such as erythropoiesis-stimulating agents (ESAs) or blood transfusion)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Ferinject® reduces or delays requirement for alternative anaemia management compared with oral iron therapy
Results from the FIND-CKD study were presented at the American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia, USA. The FIND-CKD results demonstrate that Ferinject® (ferric carboxymaltose) targeting a serum ferritin of 400-600 ug/L in patients with non-dialysis-dependent chronic kidney disease (ND-CKD) and iron deficiency anaemia significantly reduces or delays the need for alternative anaemia management (such as erythropoiesis-stimulating agents (ESAs) or blood transfusion). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Novel Anticoagulants for Stroke Prevention in AF and CKDNovel Anticoagulants for Stroke Prevention in AF and CKD
Studies show increased risk of stroke, bleeding and death in patients with chronic kidney disease and AF, so why is anticoagulation still underutilized? Expert Review of Cardiovascular Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Gene Hastens Kidney Disease Progression in African-Americans
Source: National Institute of Diabetes and Digestive and Kidney Diseases - Related MedlinePlus Pages: African American Health, Chronic Kidney Disease, Kidney Failure (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 13, 2013 Category: Consumer Health News Source Type: news

Iron deficiency in kidney disease patients on dialysis treated with investigational drug
Doctors at the North Shore-LIJ Health System presented late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. This data was presented at the American Society of Nephrology's Kidney Week 2013 in Atlanta, GA. Chronic kidney disease (CKD) is the slow loss of kidney function over time. The main function of the kidneys is to remove wastes and excess water from the body... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Kidney disease progression hastened in African-Americans by gene variant
A gene variant common in African-Americans predicts that people with that gene who also have chronic kidney disease (CKD) are twice as likely to progress to kidney failure as African-Americans without the high-risk gene and white people with CKD. People with the high-risk gene also tend to lose kidney function at twice the rate of those without the gene, according to the research, which was funded by the National Institutes of Health... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 12, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Bariatric Surgery Risk Increases With Kidney DiseaseBariatric Surgery Risk Increases With Kidney Disease
Chronic kidney disease patients achieve weight loss, but complications can be high. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2013 Category: Consumer Health News Tags: Nephrology News Source Type: news

Potassium Trap May Work in Hyperkalemia
ATLANTA (MedPage Today) -- A novel drug that selectively traps potassium ions may improve the treatment of hyperkalemia in patients with chronic kidney disease, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 11, 2013 Category: Cardiology Source Type: news

CKD in General Populations and Primary CareCKD in General Populations and Primary Care
How can clinicians in primary care settings better diagnose and manage their patients with chronic kidney disease? Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2013 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Salt restriction might prevent kidney failure and protect against heart disease
Reducing salt intake provides clear benefits for the heart and kidney health of patients with chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings point to the power of salt restriction in potentially prolonging kidney disease patients' lives. Excessive salt intake is consistently linked to increased risk of heart disease and worsening kidney function... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

Kidney disease patients who consume more vegetable protein may live longer
Increased consumption of vegetable protein was linked with prolonged survival among kidney disease patients in a new a study. The findings were presented at ASN Kidney Week at the Georgia World Congress Center in Atlanta, GA. Due to poor kidney function, toxins that are normally excreted in the urine can build up in the blood of individuals with chronic kidney disease (CKD). Research shows that compared with animal protein, vegetable protein intake in patients is linked with lower production of such toxins... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

APOL1 gene speeds kidney disease progression and failure in blacks, regardless of diabetes status
(University of Pennsylvania School of Medicine) A large study co-authored by Penn Medicine researchers published this week in the New England Journal of Medicine found that African Americans with the APOL1 gene variant experience faster progression of chronic kidney disease and have a significantly increased risk of kidney failure, regardless of their diabetes status. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 11, 2013 Category: Global & Universal Source Type: news

Nephropathy Drug Fails in Diabetes Trial (CME/CE)
ATLANTA (MedPage Today) -- An investigational agent won't slow progression of chronic kidney disease in type 2 diabetes patients, and may cause cardiovascular harm, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 9, 2013 Category: Cardiology Source Type: news

Gene hastens kidney disease progression in African-Americans
(NIH/National Institute of Diabetes and Digestive and Kidney Diseases) A gene variant common in African-Americans predicts that people with that gene who also have chronic kidney disease (CKD) are twice as likely to progress to kidney failure as African-Americans without the high-risk gene and white people with CKD. People with the high-risk gene also tend to lose kidney function at twice the rate of those without the gene, according to the research, which was funded by the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2013 Category: Global & Universal Source Type: news

Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease
(American Society of Nephrology) An investigational drug called ZS-9 demonstrated promising Phase 2 clinical trial results for treating abnormally high potassium levels in patients with chronic kidney disease.The immune drug abatacept did not provide benefits above standard treatment for patients with kidney inflammation caused by lupus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2013 Category: Global & Universal Source Type: news

Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
(North Shore-Long Island Jewish (LIJ) Health System) Doctors at the North Shore-LIJ Health System on Saturday will present late-breaking data showing that an investigational drug Triferic is well tolerated and effective in treating iron deficiency in patients with chronic kidney disease undergoing dialysis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2013 Category: Global & Universal Source Type: news